Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Umang Swami

Showing results (161-170 of 171) with videos related to

Pageof 18
Sort By:
JCO Precision Oncology|July 8, 2026
Development and Validation of a Computational Histology Artificial Intelligence-Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III TrialsChristopher J Sweeney, Vrishab Krishna, Viswesh Krishna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2023
Systemic Therapy for Melanoma: ASCO Guideline UpdateRahul Seth, Sanjiv S Agarwala, Hans Messersmith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2020
Systemic Therapy for Melanoma: ASCO GuidelineRahul Seth, Hans Messersmith, Varinder Kaur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline UpdateBryan J Schneider, Jarushka Naidoo, Bianca D Santomasso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO GuidelineBianca D Santomasso, Loretta J Nastoupil, Sherry Adkins, et al.
Nature Communications|December 16, 2025
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancerSoumyajit Roy, Yilun Sun, Maha Hussain, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 15, 2026
Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In OncologyThomas W Flaig, Philippe E Spiess, Michael Abern, et al.
Nature Medicine|August 26, 2025
Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Nature Medicine|August 14, 2025
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Clinical Genitourinary Cancer|September 6, 2024
Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint InhibitorDimitra Rafailia Bakaloudi, Rafee Talukder, Dimitrios Makrakis, et al.
Pageof 18

Showing results (161-170 of 171) with videos related to

Sort By:
Pageof 18
JCO Precision Oncology|July 8, 2026
Development and Validation of a Computational Histology Artificial Intelligence-Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III TrialsChristopher J Sweeney, Vrishab Krishna, Viswesh Krishna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2023
Systemic Therapy for Melanoma: ASCO Guideline UpdateRahul Seth, Sanjiv S Agarwala, Hans Messersmith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2020
Systemic Therapy for Melanoma: ASCO GuidelineRahul Seth, Hans Messersmith, Varinder Kaur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline UpdateBryan J Schneider, Jarushka Naidoo, Bianca D Santomasso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO GuidelineBianca D Santomasso, Loretta J Nastoupil, Sherry Adkins, et al.
Nature Communications|December 16, 2025
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancerSoumyajit Roy, Yilun Sun, Maha Hussain, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 15, 2026
Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In OncologyThomas W Flaig, Philippe E Spiess, Michael Abern, et al.
Nature Medicine|August 26, 2025
Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Nature Medicine|August 14, 2025
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Clinical Genitourinary Cancer|September 6, 2024
Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint InhibitorDimitra Rafailia Bakaloudi, Rafee Talukder, Dimitrios Makrakis, et al.
Pageof 18